FY2025 EPS Estimate for Olema Pharmaceuticals Cut by Analyst

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Analysts at Lifesci Capital lowered their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($2.28) per share for the year, down from their prior estimate of ($2.12). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday. Oppenheimer reissued an “outperform” rating and set a $25.00 target price (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday.

Olema Pharmaceuticals Trading Up 2.7 %

NASDAQ:OLMA opened at $4.23 on Friday. The stock has a market capitalization of $242.37 million, a PE ratio of -1.93 and a beta of 2.11. The firm’s 50 day moving average is $5.09 and its 200 day moving average is $8.35. Olema Pharmaceuticals has a 12 month low of $3.94 and a 12 month high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OLMA. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at $43,551,000. Lightspeed Management Company L.L.C. purchased a new position in Olema Pharmaceuticals in the fourth quarter worth $11,257,000. Paradigm Biocapital Advisors LP grew its position in Olema Pharmaceuticals by 32.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company’s stock worth $42,588,000 after acquiring an additional 1,801,370 shares in the last quarter. Avoro Capital Advisors LLC purchased a new position in Olema Pharmaceuticals in the fourth quarter worth $9,631,000. Finally, Millennium Management LLC grew its position in Olema Pharmaceuticals by 1,154.4% in the fourth quarter. Millennium Management LLC now owns 979,219 shares of the company’s stock worth $5,709,000 after acquiring an additional 901,159 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The stock was purchased at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the transaction, the insider now directly owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 19.40% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.